DPPA2

Summary

DPPA2 (developmental pluripotency associated 2, HGNC:19197) is a protein-coding gene on chromosome 3q13.13, encoding Developmental pluripotency-associated protein 2 (Q7Z7J5). Binds to target gene promoters, including NKX2-5 and SYCE1, but not GATA4, and may be involved in the maintenance of the active epigenetic status of these genes. It is a selective cancer dependency (DepMap: 21.6% of cell lines).

Predicted to enable chromatin binding activity. Predicted to be involved in system development. Predicted to act upstream of or within several processes, including epigenetic regulation of gene expression; lung-associated mesenchyme development; and positive regulation of stem cell proliferation. Located in nucleoplasm.

Source: NCBI Gene 151871 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 62 total — 1 likely-pathogenic
• Cancer dependency (DepMap): dependent in 21.6% of screened cell lines
• MANE Select transcript: NM_138815

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19197
Approved symbol	DPPA2
Name	developmental pluripotency associated 2
Location	3q13.13
Locus type	gene with protein product
Status	Approved
Aliases	PESCRG1, CT100
Ensembl gene	ENSG00000163530
Ensembl biotype	protein_coding
OMIM	614445
Entrez	151871

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 14 protein_coding

ENST00000478945, ENST00000857205, ENST00000915636, ENST00000915637, ENST00000915638, ENST00000915639, ENST00000915640, ENST00000915641, ENST00000915642, ENST00000915643, ENST00000915644, ENST00000915645, ENST00000915646, ENST00000915647

RefSeq mRNA: 1 — MANE Select: NM_138815 NM_138815

CCDS: CCDS2956

Canonical transcript exons

ENST00000478945 — 9 exons

Exon	Start	End
ENSE00001075695	109308032	109308293
ENSE00001075703	109309170	109309330
ENSE00001159055	109304475	109304670
ENSE00001159073	109309026	109309079
ENSE00001159085	109312545	109312692
ENSE00001281282	109300371	109300435
ENSE00001875369	109316284	109316517
ENSE00001875746	109293788	109294004
ENSE00001952877	109314510	109314555

Expression profiles

Bgee: expression breadth broad, 15 present calls, max score 90.51.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.1859 / max 68.5333, expressed in 52 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
43692	0.1292	47
43691	0.0567	16

Top tissues by expression

240 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	90.51	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	87.20	gold quality
buccal mucosa cell	CL:0002336	80.63	silver quality
epithelial cell of pancreas	CL:0000083	79.15	gold quality
pancreatic ductal cell	CL:0002079	78.46	silver quality
sperm	CL:0000019	64.76	gold quality
testis	UBERON:0000473	62.32	gold quality
nasal cavity epithelium	UBERON:0005384	62.25	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	61.44	gold quality
gingival epithelium	UBERON:0001949	61.22	gold quality
pons	UBERON:0000988	60.88	gold quality
cardia of stomach	UBERON:0001162	60.79	gold quality
myocardium	UBERON:0002349	60.47	gold quality
saphenous vein	UBERON:0007318	60.03	gold quality
vena cava	UBERON:0004087	59.87	gold quality
body of tongue	UBERON:0011876	59.87	gold quality
right testis	UBERON:0004534	59.85	gold quality
inferior vagus X ganglion	UBERON:0005363	59.85	gold quality
medulla oblongata	UBERON:0001896	59.81	gold quality
pericardium	UBERON:0002407	59.80	gold quality
dorsal plus ventral thalamus	UBERON:0001897	59.77	gold quality
nipple	UBERON:0002030	59.72	gold quality
subthalamic nucleus	UBERON:0001906	59.71	gold quality
ventral tegmental area	UBERON:0002691	59.71	gold quality
synovial joint	UBERON:0002217	59.65	gold quality
left testis	UBERON:0004533	59.56	gold quality
superficial temporal artery	UBERON:0001614	59.51	gold quality
substantia nigra pars compacta	UBERON:0001965	59.47	gold quality
tongue	UBERON:0001723	59.39	gold quality
pylorus	UBERON:0001166	59.34	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.60

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

20 targeting DPPA2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-2052	99.79	69.37	2031
HSA-MIR-4766-5P	99.75	69.23	2662
HSA-MIR-6839-3P	99.39	68.86	1301
HSA-MIR-19A-5P	99.36	66.93	1675
HSA-MIR-19B-1-5P	99.36	67.07	1669
HSA-MIR-19B-2-5P	99.36	67.07	1669
HSA-MIR-4506	99.34	67.47	526
HSA-MIR-4667-3P	99.26	65.45	1608
HSA-MIR-3164	99.02	68.39	1071
HSA-MIR-6820-3P	99.02	68.50	1035
HSA-MIR-3922-5P	98.77	66.53	1059
HSA-MIR-6837-3P	98.42	66.71	1149
HSA-MIR-6516-5P	98.42	70.19	1551
HSA-MIR-10395-3P	98.10	66.70	1726
HSA-MIR-5681A	97.99	67.17	1658
HSA-MIR-5694	97.06	67.70	682
HSA-MIR-3674	97.01	68.86	1171
HSA-MIR-597-5P	96.82	67.57	732

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 21.6% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 10)

• Differential expression of the embryo/cancer gene ECSA(DPPA2) in human preimplantation development. (PMID:18467432)
• ECSA/DPPA2 is a promising target for antigen-specific immunotherapy in non-small cell lung cancers (PMID:18519755)
• In normal tissues, PLAC1 expression was restricted to the placenta while DPPA2 expression was restricted to the placenta and testis. (PMID:19705800)
• Results identified a new family of pluripotency-related oncogenes consisting of DPPA2 and DPPA4. (PMID:23963736)
• A important role of HIWI and DPPA2 in tumorigenesis and also in lymph node metastasis of tumor cells. (PMID:24532429)
• results showed that DPPA2 expression was significantly correlated to the depth of tumor invasion and progression of tumor cells through advanced stages in colorectal cancer. (PMID:25497006)
• High DPPA2 Protein Expression is Associated with Gastric Cancer Metastasis (PMID:26745102)
• Dppa2/4 as a trigger of signaling pathways to promote zygote genome activation by binding to CG-rich region. (PMID:33316032)
• SPOP suppresses testicular germ cell tumors progression through ubiquitination and degradation of DPPA2. (PMID:33862460)
• Transcription Factor CTCFL Promotes Cell Proliferation, Migration, and Invasion in Gastric Cancer via Activating DPPA2. (PMID:34721660)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Dppa2	ENSMUSG00000072419
rattus_norvegicus	Dppa2	ENSRNOG00000064614

Paralogs (1): DPPA4 (ENSG00000121570)

Protein

Protein identifiers

Developmental pluripotency-associated protein 2 — Q7Z7J5 (reviewed: Q7Z7J5)

Alternative names: Pluripotent embryonic stem cell-related gene 1 protein

All UniProt accessions (1): Q7Z7J5

UniProt curated annotations — full annotation on UniProt →

Function. Binds to target gene promoters, including NKX2-5 and SYCE1, but not GATA4, and may be involved in the maintenance of the active epigenetic status of these genes.

Subunit / interactions. Interacts with DPPA4.

Subcellular location. Nucleus.

Tissue specificity. Expressed in embryonic stem cells. No expression is seen in 5 months embryo, mesenchymal stem cells, embryonic fibrocytes and adult tissues.

RefSeq proteins (1): NP_620170* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003034	SAP_dom	Domain
IPR025891	Dppa2/4_C_dom	Domain
IPR025892	Dppa2/4_central_dom	Domain
IPR039590	Dppa2/4	Family

Pfam: PF14047, PF14049

UniProt features (5 total): chain 1, domain 1, region of interest 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q7Z7J5-F1	68.63	0.32

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-9819196	Zygotic genome activation (ZGA)

MSigDB gene sets: 36 (showing top): MUELLER_PLURINET, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM5, CONRAD_STEM_CELL, GOMF_CHROMATIN_BINDING, RIZ_ERYTHROID_DIFFERENTIATION_6HR, GSE13522_WT_VS_IFNG_KO_SKIN_DN, MIKKELSEN_ES_ICP_WITH_H3K4ME3, ESC_V6.5_UP_LATE.V1_DN, NFE2L2.V2, MIR4766_5P, MIR4667_3P, MIR5694, GSE8685_IL15_ACT_IL2_STARVED_VS_IL21_ACT_IL2_STARVED_CD4_TCELL_DN, chr3q13, GSE17721_CTRL_VS_POLYIC_1H_BMDC_UP

GO Biological Process (1): system development (GO:0048731)

GO Molecular Function (2): chromatin binding (GO:0003682), protein binding (GO:0005515)

GO Cellular Component (2): nucleus (GO:0005634), nucleoplasm (GO:0005654)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Maternal to zygotic transition (MZT)	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	2
multicellular organism development	1
anatomical structure development	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1

Protein interactions and networks

STRING

588 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DPPA2	GDF3	Q9NR23	644
DPPA2	UTF1	Q5T230	634
DPPA2	ZSCAN4	Q8NAM6	623
DPPA2	DPPA3	Q6W0C5	621
DPPA2	DPPA5	A6NC42	620
DPPA2	NANOG	Q9H9S0	619
DPPA2	POU5F1	P31359	619
DPPA2	ZFP42	Q96MM3	597
DPPA2	SALL4	Q9UJQ4	592
DPPA2	ESRRB	O95718	584
DPPA2	PRDM14	Q9GZV8	583
DPPA2	SOX2	P48431	571
DPPA2	LIN28A	Q9H9Z2	533
DPPA2	TMEM38A	Q9H6F2	532
DPPA2	TMEM154	Q6P9G4	532

IntAct

36 interactions, top by confidence:

A	B	Type	Score
UBE2I	DPPA2	psi-mi:“MI:0915”(physical association)	0.560
DPPA2	FGFR3	psi-mi:“MI:0915”(physical association)	0.560
GRIN2C	DPPA2	psi-mi:“MI:0915”(physical association)	0.560
DPPA2	GSN	psi-mi:“MI:0915”(physical association)	0.560
DPPA2		psi-mi:“MI:0915”(physical association)	0.560
DPPA2	UBQLN1	psi-mi:“MI:0915”(physical association)	0.560
ZNF250	DPPA2	psi-mi:“MI:0915”(physical association)	0.370
DVL2	DPPA2	psi-mi:“MI:0915”(physical association)	0.370
MOAP1	DPPA2	psi-mi:“MI:0915”(physical association)	0.370
SETD5	DPPA2	psi-mi:“MI:0915”(physical association)	0.370
SPOP	DPPA2	psi-mi:“MI:0915”(physical association)	0.370
PBXIP1	DPPA2	psi-mi:“MI:0915”(physical association)	0.370
SDCBP2	DPPA2	psi-mi:“MI:0915”(physical association)	0.370
DPPA2	DPPA2	psi-mi:“MI:0915”(physical association)	0.370
VTA1	DPPA2	psi-mi:“MI:0915”(physical association)	0.370
AP2M1	DPPA2	psi-mi:“MI:0915”(physical association)	0.370
MCM10	DPPA2	psi-mi:“MI:0915”(physical association)	0.370
ZCCHC10	DPPA2	psi-mi:“MI:0915”(physical association)	0.370
DPPA2	DPPA4	psi-mi:“MI:0915”(physical association)	0.370
U2AF2	DPPA2	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (47): DPPA2 (Two-hybrid), DPPA2 (Two-hybrid), DPPA2 (Two-hybrid), DPPA2 (Two-hybrid), DPPA2 (Two-hybrid), DPPA2 (Two-hybrid), DPPA2 (Two-hybrid), DPPA2 (Two-hybrid), DPPA2 (Two-hybrid), DPPA2 (Two-hybrid), DPPA2 (Two-hybrid), DPPA2 (Two-hybrid), DPPA2 (Two-hybrid), DPPA2 (Two-hybrid), DPPA2 (Two-hybrid)

ESM2 similar proteins: A0A1B0GUJ8, A1A5R7, A2CJ06, A7E3N2, B1H224, B8QB46, D3Z8Y2, D3ZSP7, O55036, P0CG32, P54274, P70371, Q14BQ3, Q29RJ0, Q2HJ46, Q2T9U5, Q3TTP0, Q4R8X0, Q4R9F7, Q4VA55, Q5DTT8, Q5RBH9, Q5TKR9, Q5U310, Q5ZIX8, Q6DJS0, Q6ZQF7, Q71M44, Q7Z2W4, Q7Z7J5, Q80VH0, Q80VM8, Q8BMD7, Q8BZ21, Q8CCG4, Q8CDN1, Q8JZW8, Q8ND61, Q8TE76, Q8VD24

Diamond homologs: D3Z8Y2, Q7L190, Q7Z7J5, Q8CCG4, Q9CWH0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

62 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	50
Likely benign	5
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
929745	NM_138815.4(DPPA2):c.833T>C (p.Leu278Ser)	Likely pathogenic

SpliceAI

1675 predictions. Top by Δscore:

Variant	Effect	Δscore
3:109300341:A:AC	donor_gain	1.0000
3:109308163:TCA:T	donor_gain	1.0000
3:109309081:T:C	acceptor_gain	1.0000
3:109309081:T:TC	acceptor_gain	1.0000
3:109312688:AAATT:A	acceptor_gain	1.0000
3:109312690:ATT:A	acceptor_gain	1.0000
3:109312690:ATTC:A	acceptor_loss	1.0000
3:109312691:TT:T	acceptor_gain	1.0000
3:109312692:TC:T	acceptor_loss	1.0000
3:109312693:C:CC	acceptor_gain	1.0000
3:109312693:C:G	acceptor_loss	1.0000
3:109312694:T:C	acceptor_loss	1.0000
3:109314507:TAC:T	donor_loss	1.0000
3:109314508:A:AC	donor_gain	1.0000
3:109314508:A:AT	donor_loss	1.0000
3:109314509:C:A	donor_loss	1.0000
3:109314509:C:CG	donor_gain	1.0000
3:109314509:CCTT:C	donor_gain	1.0000
3:109314552:CACC:C	acceptor_gain	1.0000
3:109314554:CC:C	acceptor_gain	1.0000
3:109314555:CC:C	acceptor_gain	1.0000
3:109316335:A:AC	donor_gain	1.0000
3:109316336:C:CC	donor_gain	1.0000
3:109300342:T:C	donor_gain	0.9900
3:109300363:T:C	donor_gain	0.9900
3:109300369:A:AC	donor_gain	0.9900
3:109300370:C:CC	donor_gain	0.9900
3:109304563:T:TA	donor_gain	0.9900
3:109308121:G:A	donor_gain	0.9900
3:109308290:TATC:T	acceptor_gain	0.9900

AlphaMissense

1965 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:109304617:A:G	W238R	0.986
3:109304617:A:T	W238R	0.986
3:109304662:A:G	W223R	0.984
3:109304662:A:T	W223R	0.984
3:109304496:A:G	L278S	0.974
3:109304615:C:A	W238C	0.970
3:109304615:C:G	W238C	0.970
3:109300432:A:C	N286K	0.969
3:109300432:A:T	N286K	0.969
3:109304494:A:G	C279R	0.966
3:109304506:C:G	D275H	0.965
3:109304501:A:C	N276K	0.964
3:109304501:A:T	N276K	0.964
3:109304584:A:G	W249R	0.962
3:109304584:A:T	W249R	0.962
3:109304652:A:T	V226D	0.955
3:109304600:A:C	F243L	0.954
3:109304600:A:T	F243L	0.954
3:109304602:A:G	F243L	0.954
3:109304607:A:G	L241P	0.954
3:109304646:C:A	G228V	0.954
3:109309205:A:G	W103R	0.954
3:109309205:A:T	W103R	0.954
3:109304483:A:C	C282W	0.949
3:109304607:A:T	L241Q	0.949
3:109304659:A:G	C224R	0.948
3:109309067:A:C	Y119D	0.947
3:109308048:A:C	F214L	0.946
3:109308048:A:T	F214L	0.946
3:109308050:A:G	F214L	0.946

dbSNP variants (sampled 300 via entrez): RS1000105048 (3:109298709 C>G,T), RS1000232737 (3:109313943 G>A), RS1000530206 (3:109316068 CT>C), RS1000598517 (3:109314862 G>A), RS1000842087 (3:109304929 C>G), RS1000944652 (3:109310579 C>T), RS1000996907 (3:109310131 G>C), RS1001135216 (3:109309425 C>A,T), RS1001398105 (3:109298107 T>C), RS1001479348 (3:109303906 T>G), RS1001503150 (3:109302371 T>C), RS1001509154 (3:109312799 T>C,G), RS1001609977 (3:109308248 T>C), RS1001661717 (3:109318514 C>T), RS1001662243 (3:109307953 T>A)

Disease associations

OMIM: gene MIM:614445 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): primary ovarian failure (MONDO:0005387)

Orphanet (1): NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST002064_7	Corneal astigmatism	2.000000e-06
GCST009307_10	Spatial memory	3.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004874	memory performance

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

16 total (human), top 16 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, increases expression, increases methylation	7
entinostat	increases expression, affects cotreatment	2
belinostat	increases expression, affects cotreatment	2
methylmercuric chloride	increases expression	1
bisphenol A	affects cotreatment, decreases methylation	1
trichostatin A	decreases reaction, affects expression	1
butyraldehyde	increases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
Fulvestrant	decreases methylation, affects cotreatment	1
Acetaminophen	decreases expression	1
Benzo(a)pyrene	affects methylation, decreases methylation, increases methylation	1
Butyrates	increases expression	1
Nickel	affects expression, decreases reaction	1
Silicon Dioxide	decreases expression	1

Clinical trials (associated diseases)

75 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00417066	PHASE4	COMPLETED	Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
NCT00732693	PHASE4	COMPLETED	Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01853501	PHASE4	UNKNOWN	Effects of ADSC Therapy in Women With POF
NCT02783937	PHASE4	COMPLETED	Filgrastim for Premature Ovarian Insufficiency
NCT03535480	PHASE4	UNKNOWN	Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
NCT00140998	PHASE3	COMPLETED	Estrogen Treatment (Oral vs. Patches) in Turner Syndrome
NCT00001951	PHASE2	COMPLETED	Hormone Replacement in Young Women With Premature Ovarian Failure
NCT00370019	PHASE2	WITHDRAWN	Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure
NCT00429494	PHASE2	COMPLETED	GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
NCT03816852	PHASE2	SUSPENDED	The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
NCT04536467	PHASE2	UNKNOWN	Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
NCT06117982	PHASE2	COMPLETED	The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
NCT02912104	PHASE1	COMPLETED	A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure
NCT03178695	PHASE1	COMPLETED	Inovium Ovarian Rejuvenation Trials
NCT04815213	PHASE1	ACTIVE_NOT_RECRUITING	The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
NCT05138367	PHASE1	COMPLETED	Effects of UCA-PSCs in Women With POF
NCT06132542	PHASE1	UNKNOWN	Autologous ADMSC Transplantation in Patients With POI
NCT00948857	PHASE2/PHASE3	TERMINATED	Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)
NCT04031456	PHASE2/PHASE3	RECRUITING	Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
NCT02043743	PHASE1/PHASE2	UNKNOWN	Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure
NCT02062931	PHASE1/PHASE2	UNKNOWN	Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure
NCT02151890	PHASE1/PHASE2	COMPLETED	Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure
NCT02372474	PHASE1/PHASE2	COMPLETED	It is a Real The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure
NCT02603744	PHASE1/PHASE2	UNKNOWN	Autologous Adipose Derived Mesenchymal Stromal Cells Transplantation in Women With Premature Ovarian Failure (POF)
NCT02644447	PHASE1/PHASE2	COMPLETED	Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF
NCT03069209	PHASE1/PHASE2	UNKNOWN	Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)
NCT03985462	PHASE1/PHASE2	WITHDRAWN	Very Small Embryonic-like Stem Cells for Ovary
NCT04009473	PHASE1/PHASE2	UNKNOWN	Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation
NCT04071574	PHASE1/PHASE2	COMPLETED	Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility
NCT04922398	PHASE1/PHASE2	UNKNOWN	Ovarian Injection of PRP (Platelet -Rich Plasma) Vs Normal Saline in Premature Ovarian Insufficiency
NCT05462379	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment.
NCT06202547	PHASE1/PHASE2	UNKNOWN	Intra-ovarian Injection of MSC-EVs in Idiopathic Premature Ovarian Failure
NCT01129947	EARLY_PHASE1	WITHDRAWN	The Use of DHEA in Women With Premature Ovarian Failure
NCT05522634	EARLY_PHASE1	UNKNOWN	A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency
NCT07308327	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	The Influence of Gut Microbiota on Ovarian Function: A Single-center, Randomized,Double Blind, Parallel-controlled, Exploratory Clinical Trial
NCT00001275	Not specified	COMPLETED	Ovarian Follicle Function in Patients With Primary Ovarian Failure
NCT00001306	Not specified	COMPLETED	Steroid Therapy in Autoimmune Premature Ovarian Failure
NCT00006156	Not specified	COMPLETED	Feasibility Study for Development of an Early Test for Ovarian Failure
NCT00119925	Not specified	UNKNOWN	‘SPRING’-Study: Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists